These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Castellanos M; Leira R; Serena J; Blanco M; Pedraza S; Castillo J; Dávalos A Stroke; 2004 Jul; 35(7):1671-6. PubMed ID: 15166391 [TBL] [Abstract][Full Text] [Related]
7. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Molina CA; Montaner J; Abilleira S; Ibarra B; Romero F; Arenillas JF; Alvarez-Sabín J Stroke; 2001 May; 32(5):1079-84. PubMed ID: 11340213 [TBL] [Abstract][Full Text] [Related]
8. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Castellanos M; Sobrino T; Millán M; García M; Arenillas J; Nombela F; Brea D; Perez de la Ossa N; Serena J; Vivancos J; Castillo J; Dávalos A Stroke; 2007 Jun; 38(6):1855-9. PubMed ID: 17478737 [TBL] [Abstract][Full Text] [Related]
10. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Sumii T; Lo EH Stroke; 2002 Mar; 33(3):831-6. PubMed ID: 11872911 [TBL] [Abstract][Full Text] [Related]
11. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Heo JH; Kim SH; Lee KY; Kim EH; Chu CK; Nam JM Stroke; 2003 Jun; 34(6):e48-50. PubMed ID: 12750540 [TBL] [Abstract][Full Text] [Related]
12. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. Ramos-Fernandez M; Bellolio MF; Stead LG J Stroke Cerebrovasc Dis; 2011; 20(1):47-54. PubMed ID: 21044610 [TBL] [Abstract][Full Text] [Related]
16. [Correlation between the expression of proinflammatory cytokines and matrix metalloproteinases in the acute phase of an ischemic stroke]. Montaner J; Alvarez-Sabín J; Barberá G; Anglés A; Molina C; Abilleira S; Arenillas J; Chacón P; Monasterio J Rev Neurol; 2001 Jul 16-31; 33(2):115-8. PubMed ID: 11562868 [TBL] [Abstract][Full Text] [Related]
17. Variants in matrix metalloproteinase-9 gene are associated with hemorrhagic transformation in acute ischemic stroke patients with atherothrombosis, small artery disease, and cardioembolic stroke. Yi X; Sui G; Zhou Q; Wang C; Lin J; Chai Z; Zhou J Brain Behav; 2019 Jun; 9(6):e01294. PubMed ID: 31074588 [TBL] [Abstract][Full Text] [Related]
18. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Lucivero V; Prontera M; Mezzapesa DM; Petruzzellis M; Sancilio M; Tinelli A; Di Noia D; Ruggieri M; Federico F Neurol Sci; 2007 Aug; 28(4):165-70. PubMed ID: 17690845 [TBL] [Abstract][Full Text] [Related]
19. Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Fujimura M; Watanabe M; Narisawa A; Shimizu H; Tominaga T Surg Neurol; 2009 Nov; 72(5):476-80; discussion 480. PubMed ID: 19147196 [TBL] [Abstract][Full Text] [Related]
20. Analysis of risk factors of hemorrhagic transformation after acute ischemic stroke: cerebral microbleeds do not correlate with hemorrhagic transformation. Wang BG; Yang N; Lin M; Lu B Cell Biochem Biophys; 2014 Sep; 70(1):135-42. PubMed ID: 24691925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]